The program is currently being developed, keep an eye out for updates shortly


The program is currently being developed, keep an eye out for updates shortly


Please click on below the agenda to view the preliminary program and the confirmed speakers.
The information is subject to change without notice.

Microbiome 2018_Agenda


The program will be added to this page once it becomes available


The format of this workshop will consist of a one and a half days abstract-driven workshop with invited lectures, oral and poster presentations. In order to ascertain an interactive workshop setting, much time is allocated to Q&A sessions and discussions.

The main objectives of this meeting are to provide a forum for basic scientists, clinicians, virologists, epidemiologists and public health officials to present and to discuss the various aspects of transmission of HIV and the princples of intervention. The ultimate goal of the meeting is the integration of efforts from all relevant disciplines in order to constrain the spread of (drug-resistant) HIV. The program is currently being developed and will include the following topics:

  • Biology of HIV transmission
  • Virology of HIV transmission events
  • Epidemiology & modelling of HIV transmission
  • Mother-to-child transmission
  • Transmission of drug-resistance
  • Biomedical approaches for HIV prevention of sexual transmission
  • Social sciences & behavioural risk factors

We look forward to welcoming in Madrid, Spain, for this exciting event in 2018!

The 13th International Workshop on HIV Transmission will be held as an ancillary meeting to the HIVR4P, taking place from 21-25 October 2018 in Madrid. Their program can be found here






Tuesday 22 May 2018

 16:00Opening Of the Workshop
Conference Chair 
 Session 1: New Technologies and formulations
 16:15Lecture on new Injectables and the effect of having no liver passage   
yyy, USA
 16:45Guidelines of the FDA
yyy,  United Kingdom

Pharmacology of Modified Moabs
yyy, Thailand

 Session 2: 
 16:30Clinical Implementation of Pharmacogenomics 
yyy, USA
 17:45Abstract Presentation 
yyy,  United Kingdom
 16:45Abstract Presentation 
yyy,  United Kingdom

Abstract Presentation
yyy, Thailand



  18:00Welcome Reception & Poster Viewing Session I
 18:30Workshop dinner

Wednesday 23 May 2018

 8:00Morning coffee
 Session 3: Hepatitis related topic
 8:30The use of DAA's in pregnancy in HCV infected mothers
 9:00Clinical case presentation
Texas Children's Hospital, USA
 9:30Abstract presentation xxx
 9:45Abstract presentation xxx
 Session 4: 
 11:10Too small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants
Mark Mirochnick MD,
Boston University, USA
 11:40Short oral poster presentations 
 12:10Lunch & Poster Viewing
 Session 5: Adolescents
 13:30Young investigator award
 13:45The emerging pediatric population:  youth with behaviorally-acquired HIV 
Sarah Bernays, PhD,
The University of Sydney, Australia
 14:15Preventing HIV in young women in Africa – the importance of social protection
Lucie Cluver, PhD,
University of Oxford / University of Cape Town, UK / South Africa
 14:45Oral Abstact Presentations
 Session 6: 
 16:15HIV self-testing – should this be promoted for youth? Short talk and panel of researchers and youth
 16:30Discussion with speakers, adolescents and audience



The 5th edition of the International HBV Cure Workshop will again feature the world's most prominent and distinguished speakers that will discuss the most current and trending issues in the field. Delegates can look forward to an exciting and highly interactive program that will inspire and promote new strategies to advance the field. 


 Wednesday 7 November

 Session 1: Modulating approved therapies to achieve HBV Cure
 8:05What is the cure rate with current therapies?
Harry Janssen
Toronto General Hospital / University Health Network, Toronto, Canada
 8:20Stopping Nucleos(t)ide Analogues:  When is it beneficial, when is it dangerous? 
 8:35Novel molecular targets for T cell restoration strategies in chronic HBV infection
 Session 2: New Endpoints and Biomarkers
 10:00What are the pros and cons of HBsAg loss as the endpoint for treatment?
Jordan Feld
Toronto Centre for Liver Disease, Toronto, Canada
 10:15Can we measure (activity of) cccDNA in the blood?
Fabien Zoulim
INSERM, Lyon, France
 10:30Will HBsAg depletion restore HBV specific immunity?
Adam Gehring
Toronto Centre for Liver Disease, Toronto, Canada
 Session 3: Update on Immune Targets for HBV Therapy 
 11:35Rationale for modulating innate immunity: TLR, RIG- and others.
 11:50Antiviral effect of the RIG-I agonist, Inarigavir
Nezam Afdahl
Beth Israel Deaconess Medical Center, Boston, USA
 12:00Activating Toll-like receptor (TLR)-8 with GS-9688 for HBV therapy
Simon Fletcher 
Gilead Sciences, Foster City, USA
Lu Gao
Roche Innovation Center Shanghai, Shanghai, China 
 12:20Innate activation with Inactivated parapox viruses for HBV therapy - AIC649
Daniela Paulsen
AiCuris, Germany
 13:30Rationale for Modulating Adaptive Immunity: Therapeutic Vaccination, Checkpoint Inhibitor and others
Robert Thimme
University of Freiburg, Freiburg, Germany
 13:45Anti-HBV potential of PD-1/PD-L1 blockade in chronic HBV infection
 Session 4: Update on Virologic Targets for HBV Therapy
 15:00Rationale for different Virological Targets in HBV
Stephen Locarnini
Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia
 15:15Clinical progress of the entry inhibitor Myrcludex B
Stephan Urban
University of Heidelberg, Heidelberg, Germany
 15:25Establishing functional remission of HBV and HDV infection with REP 2139-based combination therapy
Andrew Vaillant
Replicor, Montreal, Canada
 15:35Clinical update on reducing HBV virus and antigen production using RNAi
 15:45Clinical update on reducing HBV virus and antigen production using RNAi
Bill Symonds,
Roivant Sciences, New York, USA
 15:55Clinical update on reducing HBV virus and antigen production using RNAi
 16:05Clinical update on antiviral effects of Capsid assembly modulators
 16:15Clinical update on antiviral effects of Capsid assembly modulators
 17:15Closure of the Workshop



HIV Pediatrics will feature an exceptional program with invited lectures, round table discussions and interactive participation from delegates. The program is published below:



Friday 20 July 2018

 08:30Opening words
Lynne Mofenson & Sibyl Geelen 
 08:45Social opening/video 
Sibyl Geelen, MD, PhD
 Session 1: Pediatric Care and Treatment
 09:00Early treatment and clinical outcomes – does early ART make a difference?   
Louise Kuhn, PhD
Columbia University Medical Center, USA
 09:15Controllers: post-treatment vs elite controllers – what do we know?
Phillip Goulder, MA, FRCPCH, DPhil, FMedSc,
University of Oxford,  United Kingdom

HIV vaccines and broadly neutralizing monoclonal antibody - role in the cure agenda
Sandhya Vasan, MD
Armed Forces Research Institute of Medical Sciences/ US Military HIV Research Program, Thailand

 09:45Roundtable: Talking with parents and children/youth about cure research
  10:45Debate: All children should be switched to dolutegravir-based ART regimens 
Nandita Sugandhi, 
Columbia University, USA 
Adeodata Kekitiinwa, MBChB, MMed
Baylor College of Medicine, Uganda
  11:15Oral Abstract Presentations
  12:30Lunch & Poster Viewing
  14:00Mobile technology for engaging children and youth in treatment and prevention
Lisa Hightow-Weidman MD, MPH,
University of North Carolina at Chapel Hill, USA
 Session 2: Comorbidities/infections
 14:30Challenges and successes in implementing rapid infant diagnostic testing 
Patricia Fassinou, MD
Elizabeth Glaser Pediatric AIDS Foundation, Cote d’Ivoire
 15:00Oral Abstract Presentations
  16:30Clinical case presentations 
Moderators: Gareth Tudor Williams & Moherndran Archary 
  High Income
Henriette Scherpbier, MD 
Emma Childrens Hospital / Academic Medical Center/ University of Amsterdam
Jason Brophy, MD
Children's Hospital of Eastern Ontario, USA
  Low Income
Tavitiya Sudjaritruk, MD, ScM, PhD,
Chiang Mai University Thailand
Grace McHugh, MBBCh, MRCPI,
Biomedical Research and Training Institute, Zimbabwe
  17:15Short oral poster presentations 
  17:30 Poster Viewing and Welcome Reception
 18:30Workshop dinner

Saturday 21 July 2018

 8:00Morning coffee
 Session 3: Prevention of Mother-to-Child Transmission
 8:30Current implementation
Shaffiq Essajee, MD,
Maria Kim, MD,
Texas Children's Hospital, USA
 9:10Debate: All infants should receive oral antiretroviral prophylaxis throughout breastfeeding 
Amy Slogrove,MB ChB, MMed, PhD,
Stellenbosch University, South Africa
Philippe van der Perre MD, PhD
University Montpellier France
 09:40Oral Abstract Presentations
 11:10Too small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants
Mark Mirochnick MD,
Boston University, USA
 11:40Short oral poster presentations 
 12:10Lunch & Poster Viewing
 Session 4: Adolescents
 13:30Young investigator award
 13:45The emerging pediatric population:  youth with behaviorally-acquired HIV 
Sarah Bernays, PhD,
The University of Sydney, Australia
 14:15Preventing HIV in young women in Africa – the importance of social protection
Lucie Cluver, PhD,
University of Oxford / University of Cape Town, UK / South Africa
 14:45Oral Abstact Presentations
 16:15HIV self-testing – should this be promoted for youth? Short talk and panel of researchers and youth
 16:30Discussion with speakers, adolescents and audience



Session topics - Capacity building sessions

APACC 2018 program will consist of basic science, clinical discussions, social perspectives, policy and capacity-building sessions directly focused on the Asia-Pacific region.

Please click below on the agenda to view the preliminary program and confirmed speakers. The information is subject to change. Also check out the satellite symposia organized by the meeting partners. 

APACC 2018_agenda


Session topics

  • Future of ART in LMICs
  • Basic science or prevention
  • Management of advanced HIV
  • Social media and mHealth
  • Optimizing clinical management of long-term complications
  • Community, +/- prevention
  • Key populations and community-led service models
  • Immune interventions to control HIV
  • Viral hepatitis
  • Debate on whether IPT should be implemented for all HIV patients in the Asia-Pacific

Capacity building sessions

 Friday 29 June 2018, Breakfast meeting
How to do a systematic review?
 What are systematic reviews used for? What are the key milestones in conducting a systematic review? Discuss with the experts and learn more about how systematic reviews are prepared.

 Nathan Ford, MPH, PHD, FRCPE Dept of HIV/AIDS and Global Hepatitis Programme at WHO


Joseph D. Tucker, MD, PhD

Joseph D. Tucker, MD, PhD, AM University of North Carolina
School of Medicine and London School of Hygiene and Tropical Medicine

 Friday 29 June 2018, Lunch symposium
Research methodology
 Learn about the basics of statistical inference and hypothesis testing, hear about the hierarchy of study designs and their strengths and weaknesses, and understand common study endpoints and learn how to interpret them.

Law, Matthew 2018 120x160

Matthew Law, BA(Hons), MSc, PhD
Biostatistics and Databases Program,
The Kirby Institute, Australia


Mark Boyd, BA, BM, BS, MHID, DCTM & H, MD, FRACP
The Kirby Institute, Australia

 Saturday 30 June 2018, Breakfast meeting
Getting involved in clinical research – from clinical trials to sub-studies
 How to formulate a question for a clinical trial? What are the steps in clinical trial design and how can you get involved in clinical trials? Learn more during this interactive session on clinical trials and sub-studies.

Nicholas Paton, MD, FRCP

Nick Paton, MD, FRCP
National University of Singapore

Thuy Le, MD, DPhil

Thuy Le, MD, DPHIL Oxford University
Clinical Research Unit, UK


Participation and registration
Please indicate which capacity building sessions you would like to join. You may join only one but you may have the greatest benefit if you participate in all three sessions!

Sign up here!

Only limited places are available, places will be given on a first-come first-serve basis.

 Poster discussion sessions directed toward research/ investigators

  • Clinical/Data
  • Research/Methodology




Thursday 11 October - Day 1

9:00 Opening of the Workshop
 Session 1: Epidemiology of HIV and hepatitis in the CEE countries
9:10Epidemiology of HIV Infection and Treatment in Europe
Teymur Noori, ECDC, Stockholm, Sweden
9:35Update on changes in Hepatitis B and C in CEE countries
Milosz Parczewski, MD, PhD, Pomeranian Medical University, Sczeczin, Poland
10:00How can new diagnostics help to increase the number diagnosed?
Francesco Marinucci, PhD, FIND, Geneva, Switzerland
10:25 Country models: what has and what hasn’t worked
11:10Coffee Break
 Session 2: Challenges in HIV and Viral Hepatitis
11:40Hepatitis Delta: what are the new developments, what are the challenges?
Cihan Yurdaydin, MD, Ankara University Medical Centre, Ankara, Turkey
12:05HIV & women's health: do we have any game changers here?
Justyna Kowalska, MD, PhD Medical University of Warsaw, Warsaw, Poland
12:30 Roundtable discussion
12:45 Group picture and Lunch
13:45 Industry-sponsored symposium
 Session 3: Switching HIV therapy: considerations and strategies
14:45 Clinical considerations in switching antiretroviral therapy
David Jilich, MD, HIV Centre Prague, Prague, Czech Republic
15:05Roundtable with short talks from a number of CEE country representatives presenting their current strategy for switching suppressed HIV patients
15:35Coffee break
16:00Abstract presentations 
16:30Clinical Case Discussion: Switching HIV Therapy
Pavel Khaykin, MD, MainFachArzt, Frankfurt, Germany
17:00Industry-sponsored symposium
18:00End of Day 1 Program: Welcome reception & Poster viewing
19:00Workshop Dinner

Friday 12 October - Day 2

 Session 4: Management of hepatitis C
8:30 Critical assessment of the global epidemiology of HCV (how reliable is the global HCV prevalence data)
Peter Ferenci, MD, University of Vienna, Vienna, Austria
08:55 Liver transplantation for HCV and HBV in The Czech Republic
Soňa Fraňková, MD, PhD, IKEM Prague transplant center, Prague, Czech Republic

Case Study: The changing IV drug use problem/pattern and what that means to the epidemic
Mojca Maticic, MD, PhD, University Medical Centre Ljubljana, Ljubljana, Slovenia

09:45The EpiTer-2 database
Robert Flisiak, MD, PhD, Medical University of Bialystok, Bialystok, Poland
10:15Coffee break
 Session 5: Management of hepatitis B
10:45Hepatitis B cure strategies: how far are we?
Heiner Wedemeyer, MD, University Clinic Essen, Essen, Germany
11:10 Abstract presentations 
11:30Industry-sponsored symposium
 Session 6: Hot topics in HIV and hepatitis
13:30New delivery systems and long acting antiretroviral drugs
David Back, PhD, University of Liverpool, Liverpool, United Kingdom
13:55HIV PreP
Christoph Spinner, PD, Technical University of Munich, Munich, Germany
14:20Abstract presentations 
15:00End of meeting









Thursday 13 September - Day 1

8:30 Opening of the workshop
Session 1: The geriatric assessment and interventions - part 1
Chair: David Moore
8:40Broad geriatrics talk
Alison Moore, MD, MPH, FACP, AGSF, University of California San Diego, USA
9:10Cognition and daily functioning
Leah Rubin, PhD, MPH, University of Illinois at Chicago, USA
9:40Abstract driven presentations
10:15Coffee break
Session 2: The geriatric assessment and interventions - part 2
10:45Physical Therapy
Kelly O'Brien, PhD, BScPT, BSc, University of Toronto, Canada
Catia Marzolini, PharmD, PhD, University Hospital Basel,  Switzerland
11:45Abstract driven presentations
12:15 Roundtable discussion
12:45 Lunch
Session 3: Mitochondrial medicine
Chair: Julian Falutz
13:45Mitochondrial dysfunction in aging
Brendan Payne, PhD, Newcastle University, U.K
14:15Cardiac function
Ahmed Tawakol, MD, Massachusetts General Hospital, Boston, USA
14:45Abstract driven presentations
15:30Coffee Break
Session 4: Managing renal functioning in Aging HIV + patients
Chair: Charles Flexner
16:00Metabolic dysfunction and cognition
Savita Pahwa, MD, University of Miami, Florida, USA
16:30Abstract driven presentations
17:15Welcome drinks and poster viewing session 1
19:00Workshop dinner (on pre-registration only)

Friday 14 September - Day 2

Session 5: Metabolic dysfunction and cognition
Chair: Scott Letendre
8:30Metabolic dysfunction and cognition
Norman Haughey, PhD, Johns Hopkins University, Baltimore, MD, USA
9:00 Abstract driven presentations
10:15Coffee break and poster viewing session 2
Session 6: Frailty and sarcopenia
Chairs: Kristine Erlandson and Cara Wilson
11:00Frailty and Sarcopenia: Identifying Prognostic Biomarkers
Monty Montano, PhD, Harvard University, Boston, Massachusetts, USA
11:30Microbiome in aging and HIV
Cara Wilson, MD, University of Colorado, USA
12:00Abstract driven presentations

Session 7: Menopause in HIV+ women
Chair: Jonathan Schapiro

13:45Menopause in HIV+ women
Sharon Walmsley, FRCPC, MD, MSc, University Health Network, Toronto, Canada
14:15Abstract driven presentations
Session 8
 15:00 Update from NIH
Maureen Goodenow, PHD, Office of AIDS Research (OAR), USA
 15:30 Roundtable discussion: policy makers perspective, patients perspective
 16:15 Closure of the workshop




To download or print the final program, download here: ICASA Symposium - Final Program 
For speaker's bio's, please click on names

Wednesday 6th December 2017

18.15 Registration and Welcome coffee/snacks
18.45 Introduction by the chairs


 The Future ART in Africa

  • Which ART are currently used in most African countries?
  • Global milestones with ART regimens with the aim of simplifying efficacy (All drugs work, the need for CD4 monitoring, need for Viral load monitoring, need for resistance testing) If the right drug is used, only Viral load monitoring may be needed 

Fransçois Venter 


 Simplifying ART Adherence

  • Clinical overview of Single Tablet Regimens (STRs)
  • Results of studies as regard to efficacy, failure and resistance development 

Mark Nelson, MD 


 Simplifying Toxicity Monitoring 

  • Requirements for monitoring 
  • Toxicity and the impact of limited monitoring 
  • Advent of new toxicities with time 

Lloyd Mulenda (Zambia) 


 What does simple therapy mean to me? (Patient experience)

Kenley Sikwese (Zambia) 


Round table discussion & Summary

 20.25 Closing Remarks



COLDA will feature an exceptional program with invited lectures, round table discussions and interactive participation from delegates.

The draft program is published below:
*Updated February 26


Thursday September 13 2018

 09:30Registration and walk in coffee
 Introduction to Viral Hepatitis and Liver Disease
 10:30Clinical spectrum of liver disease in africa
 11:00The ABC of viral hepatitis
Mark Thursz, MRCP,
Imperial College, St Mary's Hospital, UK
 11:30Essential diagnostic tools for viral hepatitis
Elijah Songok, MSc, PhD,
KEMRI, Kenya
 12:30     Opening of the Conference
               Conference Chairs

The global challenge of viral hepatitis 
John Ward, MD,
Centers for Disease Control and Prevention, USA

 Session 1: Situation of Liver Disease in Africa
 02:30Burden of Liver Disease in North Africa
Ayman Yosry, MD
Cairo University, Egypt

Burden of liver disease in Sub Saharan Africa

 03:45Patient group presentation
Gamal Shiha,
The African Association of patients with liver disease, Egypt
 04:00Coffee / Tea Break
 Session 2: HIV-Hepatitis Coinfections
  04:30HIV and its impact on viral liver disease
Mark Nelson, MD,
Chelsea and Westminster Hospital, United Kingdom
  05:00Hepatitis D - a forgotten foe?
Richard Njouom, PhD,
Centre Pasteur, Cameroon
 06:00Welcome reception

Friday September 14 2018

 08:00Morning coffee / tea
 Session 3: Hepatitis B
  08:30Whats new in hepatitis B (treatment and monitoring) 
Mark Sonderup, BPharm, MBChB, FCP(SA) MMED, 
University of Cape Town, South Africa
  09:00MTC transmission of HBV
Christian Tzeuton, MD
Douala Medical School / Société Camerounaise de Gastro-Enterologie, Cameroon
  09:30Oral abstract presentation
  09:45Oral abstract presentation
 Session 4: Hepatitis C
  10:45Who is at risk of hepatitis C in Africa?
  11:15How to treat HCV in a Resource-Limited settings
Gamal Esmat, MD,
Cairo University, Egypt
  12:00Oral abstract presentation
  12:15Oral abstract presentation
 12:45Poster viewing session & Lunch
 Session 5: Liver Disease in Special Population
 14:45Viral hepatitis in paediatrics (B and C)
Manal El-Sayed, MD,
Ain Shams University, Cairo, Egypt
 15:15Sex workers and MSM- HBV reactivation

Other special populations (PWID)
John Rwegasha, MBChB, M.MED, FRCP, MSc -
Muhimbili National Hospital, Tanzania

 Session 6: Future issues in liver disease in Africa
  4:45Alcoholic liver disease 
Kosh Agarwal, MD, King’s College Hospital, UK
  5:15Drug induced liver disease- such as AntiTb drugs
  5:45Fatty Liver disease
Maud Lemoine, MD, MSc, PhD,
Imperial College, UK
 6:30Workshop dinner

Saturday 15 September

 8:00Morning tea / Coffee
 Session 7: Other infectious liver disease
 08:30Parasitic infections (Schistosomiasis infection, Liver flukes)
Edford Sinkala,
University Teaching Hospital, Lusaka, Zambia
 09:00Hepatitis E
 10:00Tea / Coffee break
 Session 8: Clinical management of End-stage Liver Disease
 10:30Management of end-stage Liver Disease in Resource-Limited Settings
Mark Sonderup,  BPharm, MBChB, FCP(SA) MMED, 
University of Cape Town, South Africa
 11:00Management of Hepatocellular Carcinoma in Africa
Wendy Spearman, MBChB MMed PhD,
University of Cape Town, South Africa 
 11:15Oral abstract presentation
 11:30Best of Poster session: short poster presentations ( 3 slides/ 5minutes)
 Session 9: Liver Disease - Public health issues
 13:30Improving access to treatment in Resource Limited Settings
Manal El-Sayed, MD,
Ain Shams University, Cairo, Egypt
 14:00New diagnostics to improve diagnosis of liver disease
Francesco Marinucci, PhD
FIND, Italy
 14:30The dangers of not treating-modelling the viral hepatitis epidemic in Africa
Shevanthi Nayagam, MBBS,
Imperial College, UK
 15:00Tea / Coffee break
 Session 10: Round Table Discussion

How can we take the field forward:
- improve access to treatment
- increase monitoring / diagnosis
- identification special patient groups
- involvement policy makers
- standardization treatment approaches / guidelines
Karine Lacombe, MD, PHD,
Saint-Antoine Hospital, France




The Organizing Committee of the 1st International Conference on (Re-)Emerging Infectious Diseases is currently working hard on finalizing the conference program.

Below you will find the preliminary program. Please note that this program is subject to change. The final program will be announced shortly and will be made available on this website.


Day 1 -  Patterns of Emerging Diseases

 10:00Walk in coffee
 10:30 Opening of the conference 
  Session 1: Forward looking based on past experiences
 10:45General Overview on Emerging Infections globally 
 11:15Emerging infections on the African continent - The pathogen
 11:45Emerging infections on the African continent - The public health response
 12:15Panel discussion: Is the world prepared?
  Session 2: Factors facilitating outbreaks
 14:00Human - Animal contact
 14:30Impact climate change 
 Session 3
  16:30 - 17:15Invited lectures
  19:00Welcome reception

Day 2 - Managing the (re-)emerging infections 

  Session 4: Managing (re-)emerging bacterial infections - Prevention
 8:30 Potential Topic for a lecture - Surveillance / Vaccine development
 9:00 - 9:30Abstract presentation/ Real life examples
 9:45Panel discussion 
  Session 5: Managing (re-)emerging bacterial infections - Control
 11:00What's new in Antimicrobial Resistance
 11:30Clinical case presentation: Multidrug resistant TB 
 11:45Abstract - Real life examples
 12:30Poster viewing session 
 Session 6: Managing (re-)emerging viral infections - Prevention
 14:30The new epidemic of Drug Resistant HIV-1
 15:00 - 15:15Abstract - Real life examples
 Session 7: Managing (re-)emerging viral infections - Control
 16:30Zika: Where has it gone to?
 17:30Panel discussion
 18:45Workshop dinner

Day 3 - Innovations for control

  Session 8: Lessons learned 
 8:30 On the ground experience
 9:00 - 9:30How can we manage the 'Panic'
 9:45Advancing the science agenda in Africa for public health?E-tools to fight the outbreak: where do they come in?
  Session 9: How do we keep up during the outbreak? 
 11:00Ultra-rapid diagnostic testing
 11:30Fast track development of Vaccines/drugs/treatment options
 12:00Round table Discussion: What is needed to control the next outbreak?
 Session 10: Public health issues 
 13:30Where do we get the money
 14:00How do we secure care for other diseases during an outbreak
 14:30Panel discussion



Wednesday 18 October

   Session 1: Clinical Update on HBV Cure
8:30Workshop Opening & HBV update
Workshop Chairs
8:35TAF – The latest update, which questions remain to be answered?
Pietro Lampertico
, MD, PhD
University of Milan, Milan, Italy
8:50Hepatitis B Cure: From Discovery to Regulatory Endpoints in HBV clinical research: A summary of the AASLD/EASL statement
Fabien Zoulim
, MD, PhD
INSERM, Paris, France
9:05Is immunomodulation really needed to cure HBV?
Harry Janssen,
Toronto Center for Liver Disease, Toronto, Canada
9:40Coffee break
   Session 2: New biomarkers: how will they help us?
10:10How to use new virological biomarkers to assess HBV cure: quantitative HBsAg, HBcrAg, HBV-RNA
Florian Bömmel,
University of Leipzig, Leipzig, Germany
10:25To look inside or outside of the liver for evidence of HBV cure?
Georg Lauer,
Massachusetts General Hospital Boston, MA, USA
   Session 3: Latest update on New Treatment modalities - Immunologic response
11:00How does HBV interact with the immune system
Mala Maini
, MD, PhD
University College London, London, United Kingdom
11:15Innate Immunity : TLR, RIG-I, STING and potential others
Adam Gehring
, PhD
University of Toronto, Toronto, Canada
11:30Adaptive Immunity: Therapeutic vaccination, checkpoint inhibition and potential others
Andre Boonstra,
Erasmus Medical Center, Rotterdam, the Netherlands
11:45Panel Discussion
   Session 4: Latest update on New Treatment modalities - Virologic update
13:15Entry inhibition
Stefan Urban, 
Heidelberg University, Heidelberg, Germany
13:25CCC – DNA inhibition
Anuj Gaggar
Gilead Sciences, Foster City, USA
13:35RNA interference
Bill Symonds,
Arbutus, Burnaby, Canada
13:45Capsid inhibition
Angela Lam, 
Janssen, USA
13:55HBV Ribonuclease H
John Tavis
, PhD
Saint Louis University School of Medicine, Saint Louis, MO, USA
14:05Other virological mechanisms
Stephen Locarnini, BSc, PhD, MBBS, FRCP
Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia
14:15Round table discussion
15:00Coffee break
   Session 5: From the science to the clinic
15:30Is personalized therapy needed to achieve success?
Marion Peters
University of California San Francisco, San Francisco, CA, USA
15:50Combination therapy how to navigate in a minefield of efficacy and toxicity?
Jordan Feld
, MD
Toronto Centre for Liver Disease, Toronto, Canada
16:10Innovative trial design
Henry Lik Yuen Chan
, MD
Chinese University of Hong Kong, Hong Kong
16:30Round table discussion:
Trial design, treatment endpoints and regulatory approach
Bill Symonds
, PharmD - Arbutus, Canada
Jeffrey Murray, MD, MPH - U.S. Food and Drug Administration, USA
Fabien Zoulim, MD, PhD - INSERM, France
Henry Lik Yuen Chan, MD - Chinese University of Hong Kong, Hong Kong
Marion Peters, MD - University of California San Francisco, USA
Pietro Lampertico, MD, PhD - University of Milan, Italy
17:30Closure of workshop






Opening Remarks: Science Drives Success
Raymond F Schinazi
Emory University

INVESTING IN A CURE: No One Creates Success Alone
Chairs: Ana Lok, Michigan University, USA - Hélène Strick-Marchand, Pasteur, France
 15:10Plenary Presentation
Eliminating Hepatitis C by 2030 -  Enhancing Prevention Care and Treatment Among People who Inject Drugs
Margaret Hellard
Monash University, Australia
 15:50Strategy for the Elimination of Hepatitis B and C (Academy of Medicine Report)
Andrew Aronsohn
University of Chicago, USA
 16:10Elimination of HCV: The DC Story
Henry Masur
 16:30The French and European Approach Towards Hepatitis Elimination
Tarik Asselah
Hôpital Beaujon, France
 16:50Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Ana Lok
Michigan University, USA
 17:10Global Strategies to Eliminate Hepatitis B (ICE-HBV)
Peter Revill
Victorian Infectious Diseases Reference Laboratory, Australia

Epidemiologic impact of expanding chronic hepatitis C (CHC) treatment in people who inject drugs (PWID) in the United States (US): a mathematical model using data from the C-EDGE CO-STAR Study
Michael Robertson, Merck, USA


Novel Nucleosides, CMCP and CFCP, Potently Block the Infectivity and Replication of Wild-type and Drug-resistant HBVs in Culture and in Human-liver-chimeric Mice and Show Potential QW or Q2W (64)
Hiroaki Mitsuya, National Institutes of Health, USA

17:50Welcome Reception


Chairs: Francis Chisari; The Scripps Research Institute, USA - Harvey Alter; National Institutes of Health, USA
 8:00Introduction and Presentation of the William H. Prusoff HEP DART Lifetime Achievement Award
Raymond F. Schinazi
Emory University
 8:10Introduction by Joan Block
 8:20William H. Prusoff HEP DART Lifetime Achievement Award Lecture:
Access to HIV, HBV, and HCV Antiviral Agents Globally 

John Martin
Gilead Sciences, USA
Chairs: Jake Liang, National Institutes of Health, USA - Jeffrey Glenn, Stanford University, USA
 9:00Plenary Presentation
Liver Disease in Chinese-perspective from a Hepatologist
George Lau
Humanity & Health Medical Group, Hong Kong
 9:40DAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination
Jason Grebely
University of New South Wales, Australia
 10:30Short Duration DAA HCV Therapy: How Short Can We Go?
Shyamasundaran Kottilil
University of Maryland, USA
 10:50A Tale of Two Viruses: HBV and HCV Co-Infection
Jake Liang
 11:10The Global Burden of Non-Alcoholic Steatohepatitis
Zobair Younossi
Inova Health System, USA
 11:30Special Lecture
Hepatitis B/C and NASH: Crossroads Between Science and Business

Geoffrey Meacham
Barclays Biotech/Pharma Research, USA
12:00Panel Discussion

Elucidating the structural and dynamic mechanism of resistance for clinically relevant variants against HCV NS3/4A protease inhibitors
Ashley Matthew; University Of Massachusetts Medical School, USA


Real-world utilization and effectiveness of elbasvir/grazoprevir in adult patients with chronic hepatitis C in Canada: Z-PROFILE study
Edward Tam; Merck Canada Inc., Canada

Chairs: Fabien Zoulim, University of Lyon, France - Stephen Locarnini; Victorian Infectious Diseases Reference Laboratory, Australia
 15:30Plenary Presentation
Catch Me If You Can – Tuning Immunity for HBV Cure

Ulrike Protzer
Technical University of Munich, Germany
 16:10Immunology of HBV
Adam Gehring
Toronto Centre for Liver Disease, Canada
 16:30Optimizing Infection Systems and Screens and Studying Innate anti-HBV Factors and Mechanisms
Lefteris Michailidis
Rockefeller University, USA
Moderators: Mark Sulkowski; The Johns Hopkins University, USA - Raymond F. Schinazi; Emory University, USA
 17:20Special Lecture
Personalized Approaches to HBV Cure

Marion Peters
University of California, USA
 Debate: Is Host Genome Integrated HBV Relevant?
 17:50The Con Perspective
Stephen Locarnini
Victorian Infectious Diseases Reference Laboratory, Australia
 18:10The Pro Perspective
Christian Brechot
Global Virus Network, USA
 18:30Panel Discussion


Chairs: Eugene Schiff, University of Miami, USA - Ulrike Protzer; Technical University of Munich, Germany
8:00Plenary Presentation
Endpoints and New Targets for Curing Hepatitis B
Stephen Locarnini
Victorian Infectious Diseases Reference Laboratory, Australia
8:40Targeting the HBV-Macrophage-Stellate cell axis to treat HBV-induced Liver Diseases
Lishan Su
University of North Carolina at Chapel Hill, USA
9:00Core Antibody: anti-HBc What is the Core of the Story?
Robert Gish
Hepatitis B Foundation, USA
9:20Development of Immune Competent Small Animal Models for HBV
Hélène Strick-Marchand
Pasteur Institute, France
9:40Panel Discussion

In vivo evaluation of anti-HBV CRISPR/Cas9 Therapy in the FRG mouse
Keith Jerome; Fred Hutchinson Cancer Research Center, USA


A Novel Immunotherapy for Chronic HBV and HDV Infections that Bypass Tolerance and Induce Broadly Crossreactive and Neutralizing Antibodies
Matti Sallberg; Karolinska Institutet, Sweden


Chairs: Tarik Asselah; Hôpital Beaujon, France -
Paul Pockros, Scripps Translational Science Institute, USA

10:40Plenary Presentation
Revisiting the Molecular and Cell Biology of the Hepatitis B Virus Towards Elimination
Fabien Zoulim
University of Lyon, France
 11:20Distinct cellular entry pathways for quasi-enveloped and naked hepatitis A virions 
Stanley Lemon
University of North Carolina at Chapel Hill, USA
 11:40Emerging Therapeutic Targets and Concepts for Delta Hepatitis Virus
Jeffrey Glenn
Stanford University, USA
 12:00HEV Update: Diagnostics and Management
Kenneth Sherman
University of Cincinnati, USA
 12:20Panel Discussion

Chairs: Marion Peters, University of California, San Francisco - Timothy Block; Hepatitis B Foundation, USA

 A Round Table Discussion - Looming Challenges and Questions in the Cure for Chronic Hepatitis B
 13:35Is There a Best Direct Acting Antiviral in Development?
Fabien Zoulim; University of Lyon, France
 13:47Is There a Best Host Acting Antiviral in Development?
Jake Liang; National Institutes of Health, USA 
 13:59Is There a Best Immunomodulator in Development?
Ulrike Protzer; Technical University of Munich, Germany
 14:10Discussion by Panel and Audience
 14:30Closing Remarks
 15:30Poster Session
 17:00Review of Poster Presentations
Adrian Ray; Gilead Sciences, USA
Harvey Alter; National Institutes of Health, USA
Chairs: Kenneth Sherman; University of Cincinnati, USA - Stanley Lemon; University of North Carolina at Chapel Hill, USA
 17:50New directions towards functional cure of Chronic Hepatitis B
Lawrence Blatt
Janssen, USA
 18:10Looking back to move forward: designing next-gen RNAi for best results in HBV
Bruce Given
Arrowhead Pharmaceuticals, USA
 18:30SB 9200: A novel RIG-I agonist for chronic hepatitis B 
Stephen Locarnini
Victorian Infectious Diseases Reference Laboratory, Australia
 18:50Controlling HBsAg as a Key Component of a Combination Strategy to Affect an HBV Cure 
Michael Sofia
Arbutus Biopharma, USA
 19:10Immunotherapy is coming for HCC 
Spiros Hiotis
Mount Sinai Hospital, New York, USA.
 19:30Studies of the HBV-immune modulator AIC649
Helga Rübsamen-Schaeff
AiCuris, Germany


Chair: George Lau; Humanity and Health Liver Clinic, Hong Kong - Charles Boucher; Erasmus University, The Netherlands
 8:00Plenary Presentation
Clinical Challenges in HCV infection
Mark Sulkowski
Johns Hopkins University, USA
 8:40Eliminating HCV Transmission by Enhancing Care and Treatment Among HCV/HIV Co-infected Individuals in Australia
Joseph Doyle
Monash University, Australia
 9:00Management of HCV in Decompensated liver disease
Michael Manns
Hannover Medical School, Germany
 9:20When are we done? How long do we follow patients with advanced fibrosis or cirrhosis after SVR?
Paul Pockros
Scripps Translational Science Institute, USA
 9:40Panel Discussion
Margaret Hellard; Monash University, Australia - Michael Fried; University of North Carolina at Chapel Hill, USA
 10:20Plenary Presentation
DAA Controversies: Do they Cause HBV Reactivation and/or HCC?
Jordan Feld
Toronto General Hospital, Canada
 11:00Pan-genotypic direct-acting antiviral agents: Opportunity to achieve HCV elimination
Tarik Asselah
Hôpital Beaujon, France
 11:20Update on Merck’s HCV Program  
Michael Robertson
Merck, USA

Long term follow-up after Treatment with Ombitasvir/Paritaprevir/ritonavir ± Dasabuvir ± Ribavirin in the AMBER – Real World Experience Study
Robert Flisiak, Medical University of Bialystok, Poland


A Next Generation HBV Capsid Inhibitor, AB-506: In Vitro and In Vivo Antiviral Characterization (67)
Nagraj Mani, Arbutus Biopharma Inc., USA


Predicting Susceptibility and Resistance for Hepatitis B Virus Capsid Assembly Effectors
Bryan Cox, Emory University, USA

Chairs: Veronica Miller; Forum for Collaborative HIV Research, USA - Manal El-Sayed; Ain Shams University, Egypt
 15:30Plenary Presentation
NASH Globally: Pathways to Combination Therapy, Biomarkers and Outcomes
Arun Sanyal
Virginia Commonwealth University, USA
 16:10The Re-vival of Bile Acid Based Therapeutics for Children and Adults
Saul Karpen
Emory University, USA
 16:30Evolving Role of Real-World Evidence in NASH and HCC: From Bench to Poolside
Michael Fried
University of North Carolina at Chapel Hill, USA

Robert Gish, Hepatitis B Foundation, USA - Mario Stevenson, University of Miami, USA


Sustained SVR 2 years after HCV treatment with simeprevir, daclatasvir and sofosbuvir in patients with portal hypertension or decompensated liver disease
Eric Lawitz; Texas Liver Institute, USA


High Efficacy and Safety of the combination HCV Regimen Grazoprevir and Elbasvir for 8 Weeks in Treatment-Naive, non-severe fibrosis HCV GT1b-Infected Patients: Interim Results of the STREAGER study
Brigitte Chanteranne; CHU Estaing, France

ELIMINATION, PREVENTION AND VACCINE Chairs: Frank Chisari, The Scripps Research Institute, USA - Michael Manns, Hannover Medical School, Germany
 17:30Plenary Presentation
Are we Getting Closer to an HCV Vaccine? 
Andrea Cox
Johns Hopkins University, USA

Lessons learned towards a Vaccine and Functional Cure for HIV
Mario Stevenson
University of Miami, USA


Hepatitis B virus splice variants are associated with and predictive of liver cancer (12)
Peter Revill, Victorian Infectious Diseases Reference Laboratory, Australia


Seroclearance of HBsAg in Chronic Hepatitis B Virus Patients on Lamivudine, Tenofovir or Entecavir Therapy: A 10 Year Experience.
Suzane K. Ono Nita, University of Saõ Paulo, Brazil

18:40Adjourn to Closing Dinner


Chairs: Henry Masur; NIH, USA - Saul Karpen; Emory University, USA
 8:00Plenary Presentation
The Effectiveness of Treatment for Chronic Hepatitis C (and Hepatitis B) in Pediatric Populations

Manal H. El-Sayed
Ain Shams University, Egypt
 8:40Liver Directed Acetyl CoA Carboxylase Inhibitor GS-0976 For NASH
Adrian Ray
Gilead Sciences, USA

Aramchol for NASH and beyond: From Scientific Rationale to Clinical Development. 
Carol Brosgart
University of California, San Francisco, USA

 9:20Regulatory Landscape for NASH
Veronica Miller
Forum for Collaborative HIV Research, USA
 9:40Immunotherapies and treatments for HCC
ORAL ABSTRACT SESSION VII Chairs: Jason Grebely, The University of New South Wales, Australia - Shyamasundaran Kottilil, University of Maryland, USA

RNA Interference Screen Identified Farnesoid X Receptor (FXR) as a Host Dependency Factor for HBV Establishment in Primary Human Hepatocytes
Sumantra Ghosh; Gilead Sciences Inc, USA


Evidence Supporting Liver Targeting of Tenofovir Exalidex (TXL)
Robert Foster; ContraVir Pharmaceuticals Inc., USA


Two Doses of HEPLISAV-B™, a Hepatitis B Vaccine with a TLR9 Adjuvant, Compared with Three Doses of Alum-Adjuvanted ENGERIX-B® in Adults Aged 18 -70 Years
Randall Hyer; Dynavax, USA


An Integrated Multidisciplinary Approach for Prediction of Fibrosis Progression and HCC Development in Chronic Hepatitis C Infected Patients Utilizing Genomics, Elastography, Imaging and Circulating Tumor Cells
Emmanuel Thomas; University of Miami, USA


Delayed viral suppression during antiviral therapy increases hepatocellular carcinoma in HBeAg-positive chronic hepatitis B
Yoon Jun Kim, Seoul National University Hospital, South Korea


Establishment of Functional Control and Normalization of Liver Function in HBeAg Negative Chronic HBV infection Following Combined Therapy with REP 2139 or REP 2165, Tenofovir Disoproxil Fumarate and Pegylated Interferon α-2a.
Andrew Vaillant; Replicor Inc., Canada


Validation of a novel Transient Elastography for the Measurement of liver fibrosis
Jing Chen; Humanity and Health Research Centre, Hong Kong

 11:402018 & Beyond: Shifting the conversation
Eugene Schiff
University of Miami, USA

Closing Remarks
Raymond F. Schinazi
Emory University, USA



An exciting program has been set up by the members of the Program Committee.
Program 9th HIV Pediatrics









IVHEM 2017 will feature an exceptional program with invited lectures, round table discussions and interactive participation from delegates. The program is published below:

Subscribe to our newsletter to stay up-to-date on IVHEM 2017


Friday 17 November 2017

By the workshop chairs
 13:05Setting the stage - Key challenges in elimination
Jordan Feld, MD, MPH | Biography
Research Director and Clinician-Scientist, Toronto Centre for Liver Disease, Toronto, Canada
  Session 1: Test and screening strategies
Chairs: Michael Ninburg & Maia Butshashvili
 13:20 WHO status report: Global response to the strategic framework;
Yvan Hutin, MD, PhD | Biography
 13:40Global response to the strategic framework; Technologies perspective
Francesco Marinucci, PhD | Biography
Head of HIV/HCV Unit, FIND, Geneva, Switzerland 
 14:00Real-life experiences - Egypt
Imam Waked, MD | Biography
Professor of Medicine, National Liver Institute, Shebeen El-Kom, Egypt
 14:10Real-life experiences - USA
A. Blythe Ryerson, MD, PhD | Biography
Lead Epidemiologist, Division of Cancer Prevention and Control, Atlanta, GA, USA
 15:00Coffee break
  Session 2: Care & cure strategies
Chairs: Jordan Feld & Manal El-Sayed
 15:30Global trends in burden of disease
Graham Cooke, MD, PhD | Biography
Clinician scientist, Imperial College London, London, UK
 15:50How to measure your success; globally and locally
Yvan Hutin, MD, PhD | Biography 
 16:10Real-life experiences - bottlenecks & hurdles
  Jordan Feld, MD, MPH | Biography
Research Director and Clinician-Scientist, Toronto Centre for Liver Disease, Toronto, Canada
  Manal El-Sayed, MD | Biography
Professor of Pediatrics, Ain Shams University, Cairo, Egypt
  Panel Members:
  Charles Boucher MD, PhD | Biography
Professor Virology, Erasmus Medical Center, Rotterdam, The Netherlands 
  Maria Cássia Jacintho Mendes Correa, MD |
Sao Paulo University-Medical School, Brazil
  Margaret Hellard, MBBS, FRACP, FAFPHM, PhD | Biography
Head Centre for Population Health, Burnet Institute, Melbourne, Australia
  Khin Pyone Kyi, MD, PhD | Biography
President of Board of Directors, Myanmar Liver Foundation
  Jeffrey Lazarus | Biography
Copenhagen University Hospital, Denmark
  Olufunmilayo Lesi, FF9WACP, FMCP | Biography
Professor & Head, Gastroenterology and Hepatology Unit, University of Lagos & Lagos University Teaching Hospital, Lagos, Nigeria
  Huma Qureshi, MD | Biography
Pakistan Medical Research Council, Islamabad, Pakistan 
  A. Blythe Ryerson MD, | Biography
Lead Epidemiologist, Division of Cancer Prevention and Control, Atlanta, GA, USA
 17:40Lessons learned - approaches to bottlenecks and hurdles
 18:00Networking and poster reception
 19:00 Workshop dinner

Saturday 18 November 2017

 7:30Early bird coffee
 Session 3: Prevention & screening strategies
Chairs: Olufunmilayo Lesi & Francesco Marinucci / Ryan Clary
  8:00Prevention transmission strategies on treatment - Pediatric population
Manal El-Sayed, MD | Biography
Professor of Pediatrics, Ain Shams University, Cairo, Egypt
  8:20Prevention transmission strategies prior to infection - People who inject drugs
Diana Sylvestre, MD | Biography
Executive Director, O.A.S.I.S. Clinic, Oakland, CA, USA
  8:40Prevention transmission strategies prior to infection - Incarceration
Lara Strick MD, MS | Biography
Infectious Disease Physician, Washington Department of Corrections, Turnwater, WA, USA & Clinical Assistant Professor, University of Washington, Seattle, WA, USA 
  9:00Prevention transmission strategies through strengthening the health system
Maia Butshashvili, MD, MS, PhD | Biography
Health Research Union (HRU)
  9:20Panel discussion
 10:00Coffee break
 Session 4: Innovative models to finance the health care problem
Chairs: Margaret Hellard & Charles Boucher
  10:30Poster Presentations
  11:30Medicines Patent Pool’s approach to scale up access to HIV and HCV treatment
Esteban Burrone
Head of Policy, Medicines Patent Pool, Switzerland
 12:00Micro-elimination as a strategy to reach global elimination
Jeffrey Lazarus| Biography
ISGlobal, Hospital Clínic, University of Barcelona
  12:30Closing Remarks



The Organizing Committee proudly presents the preliminary workshop program:


Wednesday 14 June 2017

16:00Workshop Opening
Angela Kashuba, PharmD and David Burger, PharmD, PhD
  Session 1: Approaches to Treating CMV and Influenza
16:15 Current and Future Treatment of CMV
Robin Avery, MD - Johns Hopkins University, USA
16:45O_1: Single- and multiple-ascending doses (SAD/MAD) and food effect of orally administered JNJ-64155806 in healthy volunteers
Dr Thomas Kakuda
  Session 2: The Complexity of DDIs Involving PK Enhancement
17:00O_2: Effects of cobicistat on tenofovir durability: is it time to rethink at TAF trials?
Dr Dario Cattaneo
17:15O_3: Pharmacokinetics of darunavir/cobicistat and etravirine alone and coadministered in HIV-infected patients
Dr Jose Molto
17:30O_4: Evaluation of the Drug-Drug Interaction Potential between Cobicistat-Boosted Protease Inhibitors and Statins
Dr Joseph Custodio
17:45O_5: Confirmation of the drug-drug interaction (DDI) potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives
Dr Sophia Majeed
18:00O_6: Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir
Dr Catia Marzolini
18:30End of Plenary Session - Poster Viewing (Posters 22 to 33) & Welcome Reception

Thursday 15 June 2017

  Session 3: Challenges and Approaches to Treatment in Special Patient Populations
8:30 Current Challenges in Pediatric Drug Development 
Robert Ward, MD, FAAP, FCP - University of Utah, USA
9:00 Clinical Aspects of Pediatric Treatment
Tim Cressey, PhD - Chiang Mai University, Thailand
9:30O_7: A Comparison of the Pharmacokinetics of Dolutegravir during Pregnancy and Postpartum
Dr Pauline Bollen
9:45O_8: Relationship between dolutegravir plasma exposure, quality of sleep and its functional outcome in patients living with HIV over the age of 60 years.
Dr Marta Boffito
10:15Coffee break + Poster Viewing (Posters 34 to 50) + Group Picture
  Session 4: Hepatitis B Virus
11:45 HBV therapy & Approaches to Cure
Jordan Feld, MD, MPH - Toronto Western Hospital Liver Center, Canada
  Session 5: Exploration of Less-drug Regimens
12:30O_10: Pharmacokinetics of Dolutegravir and Rilpivirine after Switching to the Two-Drug Regimen from an Efavirenz- or Nevirapine-Based Antiretroviral Regimen: SWORD-1/2 Pooled PK Analysis
Dr Kimberly Adkison
12:45O_11: HIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract.
Dr Sandrine Lefeuvre
  Session 6: Implications of Drug Transport and Metabolism in Drug Development
14:15 Transporter mediated DDI
Kathy Giacomini, PhD - University of California, San Francisco, USA
14:45 FDA perspective
Kellie Reynolds, PharmD - U.S. Food & Drug Administration, USA
15:15O_12: Examining the Basis of Drug-Drug Interaction Labeling Recommendations for Antiviral Approvals from 1998 to 2015
Dr Tyler Shugg
15:30O_13: CYP3A induction data can predict other P450 and drug transporter DDI liability: An example of carbamazepine and rifabutin with sofosbuvir and P-gp
Dr. Brian Kirby 
16:00Coffee break
  Session 7: Clinical Cases
Clinical Case Discussions
16:30 Challenges in managing the aging HIV-infected patient
Babafemi Taiwo, MBBS - Northwestern University, USA
17:00 DDI’s in Aging HIV infected Patients
Alice Pau, PharmD - National Institutes of Health, USA
17:30 DDI’s in Aging HCV infected Patients
Elise Smolders, MSc - Radboudumc Nijmegen, The Netherlands
18:00End of Plenary Session - Workshop Dinner

Friday 16 June 2017

  Session 8: Long Acting Antivirals: Advanced drug delivery
8:30 Long Acting Antivirals: Advanced drug delivery
Mark Milad, PharmD - Bill & Melinda Gates Foundation, USA
9:00O_14: Pharmacokinetics of Co-encapsulated Truvada® with Ingestible Sensor to Assess Adherence
Dr Nathan Hanan
9:15O_15: Identification of long-acting NRTI candidates through in silico modelling
Dr Marco Siccardi
9:30O_16: A mathematical model that predicts virological failure and elucidates the impact of lymph node drug penetration
Dr Steven Sanche
9:45O_17: Early Safety, Tolerability, and Pharmacokinetic Profile of GSK2838232, a Novel 2nd Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects
Dr Mark Johnson
10:15Coffee break + Poster Viewing (Posters 51 to 60)
  Session 9: Hepatitis C Virus
11:00O_18: Drug-drug interactions of Glecaprevir and Pibrentasvir with Pravastatin, Rosuvastatin, or Dabigatran etexilate
Dr Matthew Kosloski
11:15O_19: Influences on Pharmacokinetics of ledipasvir, sofosbuvir and GS-331007 in patients with decompensated cirrhosis – results from the UK Expanded Access programme.
Dr Omar Elsherif
11:30O_20: Evaluation of Drug-Drug Interactions between Sofosbuvir/Velpatasvir/Voxilaprevir and Boosted or Unboosted HIV Antiretroviral Regimens
Dr. Kimberly Garrison
11:45O_21: The Potential Role of PK-Based Drug Interactions in FAERS-Reported Rhabdomyolysis Cases in Patients Receiving a DAA Regimen and a Statin
Dr Su-young Choi
Debate: Do we need more HCV Drugs?
12:00 Pro Standpoint
Nancy Reau, MD - Rush University Medical Center, USA
12:15 Con Standpoint
Jürgen Rockstroh, MD - University of Bonn, Germany
  Session 10: Challenges in Drug Development for Other Viruses Than HIV or Hepatitis
14:00 Merck: CMV 
 Cyrus Badshah, MD, PhD  - Merck, USA
14:15 Janssen: Influenza
Thomas Kakuda, PharmD - Janssen/Alios, USA
14:30 Gilead: RSV
Polina German, PharmD - Gilead, USA
15:00Closure of the Workshop

The following invited speakers have confirmed their contribution to the workshop:




The program is currently being developed, keep an eye out for updates shortly











The final agenda for the 1st Andean Pacific Workshop on HIV and Hepatitis is listed below. 

Download a PDF of the program here.

ANDEAN Pacific - Online program(1)

Friday 30 June - Day 1

8:15 - 9:15Symposium - Chilean AIDS Cohort
9:15Workshop opening 
Carlos Beltrán, MD
  Session 1: Challenges for HIV care in Latin America
9:30HIV in Latin America: 35 years later
Marcelo Wolff, MD , FACP, FIDSA
Universidad de Chile, Santiago, Chile
10:00WHO Target 90-90-90 : Achievable for Latin America
Alejandro Afani, MD, FACP
Universidad de Chile, Santiago, Chile
10:30Difficult to reach populations in Latin America
Ana Paulina Celi, MD
Asociación Panamericana de Infectología, Quito,
11:15Coffee Break
  Session 2: Prevention of transmission
11:45New approaches for preventing transmission
Charles Boucher, MD, PhD
Erasmus Medical Center, Rotterdam, The Netherlands
12:15State-of-the-art lecture on PrEP
Mauro Schechter, MD, PhD
Federal University of Rio de Janeiro, Rio de Janeiro, Brasil
  Session 3: Clinical strategies
14:00Clinical Implications of low level viremia/failure and resistance
Francesca Ceccherini, MD
University of Rome Tor Vergata, Rome, Italy
14:30Abstract driven presentations
15:45Coffee break
  Session 4: Diagnostic tools
16:15Early Diagnosis & Testing
Susana Cabrera, MD
Universidad de la República, Montevideo, Uruguay
16:45Abstract-driven presentations
18:00- 19:00Symposium - MSD

Saturday 1 July - Day 2

  Session 5: Viral Hepatitis in Latin America
9:00Local situation in LA (epidemiology / treatment options)
Jorge Contreras, MD
Clínica Alemana - Universidad del Desarrollo Chile, Santiago, Chile
9:30Implementation of DAAs in clinical management
Mark Nelson, MD, PhD
Chelsea and Westminter Hospital, London, UK
10:00Strategies for Hepatitis C Elimination
Francesca Ceccherini, PhD
University of Rome Tor Vergata, Rome, Italy
10:45Poster viewing & Coffee break
  Session 6: Special Populations
14:00HIV- Hepatitis co-infected patients
Pedro Cahn, MD, PhD
Fundación Huésped, Buenos Aires, Argentina
14:30HIV in Woment - pregnancy
Isabel Cassetti, MD
Fundación Helios Salud, Buenos Aires, Argentina
15:00The aging HIV infected patient - neurological issues - poly pharmacy
Ernesto Martinez Buitrago, MD
Universidad del Valle, Cali, Colombia
16:00Coffee Break
  Session 7: ARV therapy: present and future
16:30Do we really need new drugs?
Mark Nelson, MD, PhD
Chelsea and Westminer Hospital, London, UK
16:50Present and future of ART in Latin America
Carlos Beltrán, MD
Chilean AIDS Cohort (ChiAC), Santiago, Chile
17:10HIV cure and eradication
Ricardo Diaz, MD, PhD
NIFESP Laboratorio de Retrovirologia, São Paulo, Brasil
17:30Panel discussion: Strategies for simplication
18:00Closure of the workshop




An exciting and interactive program is currently being established. You will have ample chance to meet the experts and discuss cases in smaller break-out groups. You can also look forward to invited lectures, oral abstract presentations, poster presentations and discussions. Join us and learn about the various approaches and treatments in Europe and take part in shaping innovative healthcare for the future.

​Download the preliminary program agenda (version: June 2017).


Saturday, 1 October



Final program is now available!

To download the program, please follow this link:  7th HIV & Aging_PROGRAM


Invited speakers:











View the IVHEM 2016 program below:

Friday 2 December

13.00hOpening of the workshop
by the Workshop Chairs
13.15hOpening lecture on WHO programs
Gottfried Hirnschall

Head, HIV/Viral Hepatitis Department
World Health Organization, USA
  Session 1: Results of National programs: Barriers & Successes
13.45hNational perspectives in Europe - common themes and challenges
Angelos Hatzakis
Professor of Epidemiology and Preventive Medicine
Athens University Medical School, Athens Greece
Co-Chair, Hepatitis B and C Public Policy Association
14.15hNational Programs - the Netherlands
Anouk Urbanus

‎Policy Advisor Infectious Diseases
National Institute of Public Health and the Environment, Bilthoven, the Netherlands
14.30hNational Programs - Egypt
Wahid Doss 
Professor, Cairo University, Cairo, Egypt
Head, National Committee for Control of Viral Hepatitis, Egypt
 14.45hNational Programs - Australia
Margaret Hellard
Head, Centre for Population Health
Burnet Institute, Melbourne, Australia
15.00hNational Programs - US
John Ward
Director, Viral Hepatitis Program
Centers of Disease Control and Prevention, Atlanta, USA
15.45hGroup Picture
16.00hCoffee Break
  Session 2: Progress towards elimination - Specific Populations
16.30hProgress towards elimination in the Australian prison sector
Andrew Lloyd 
Infectious Diseases Physician & Prisoner Health Researcher
Kirby Institute, University of New South Wales, and Justice Health & Forensic Mental Health Network, Sydney, Australia
16.50hChildren & Pregnant women
Manal El-Sayed
Professor of Pediatrics
Ain Shams University, Cairo, Egypt
17.10hPeople who inject drugs
Olav Dalgard
Professor of Infectious Diseases
Akershus University Hospital, Lørenskog, Norway
18.00hEnd of Day 1
A Networking reception and Workshop dinner are organized after the last session.

Saturday 3 December

  Session 3: Diagnosing
08.30hWHO Guidelines and Policies of testing
Margaret Hellard
Head, Centre for Population Health
Burnet Institute, Melbourne, Australia
08.50hProgess in testing technologies
Dmytro Donchuk
Infectious Diseases Specialist, HIV, TB and Viral Hepatitis Adviser
Médecins Sans Frontières, Brussels, Belgium
09.10hChallenges in Monitoring (POC)
Isabelle Andrieux-Meyer
HIV/HCV Team Lead
Drugs for Neglected Diseases initiative, Frontières, Geneva, Switzerland
09.30hChallenges in regards to resistance
Mark Nelson
Consultant Physician
Chelsea and Westminster Hospital, London, United Kingdom
10.00hCoffee Break
  Session 4: Reducing Transmission and harm
10.30hGlobal Injection Safety Campaign and Prevention Strategies
Arshad Altaf 

Consultant Injection Safety
World Health Organization, Geneva, Switzerland
10.50hCan we afford not to treat reinfection 
Peter Vickerman
Professor of Infectious Disease Modelling
University of Bristol, Bristol, United Kingdom
11.10hCreating awareness and sharing the knowledge
Anya Sarang
Andrey Rylkov Foundation for Health and Social Justice, Moscow, Russia
11.30hCommunity and harm reduction response to infection and reinfection
Eberhard Schatz
Coordinator European Initiative on Hepatitis C and Drug Use
Correlation Network c/o Foundation De Regenboog Groep, Amsterdam, the Netherlands
  Session 5: Future scenarios for elimination
13.15hVaccine development and results
Andrea Cox 
Professor of Medicine
Johns Hopkins School of Medicine Baltimore, MD, USA
13.35hMinimising treatment duration and doses
Jordan Feld
Research Director and Clinician-Scientist
Toronto Centre for Liver Disease, Toronto, Canada
13.55hRole of generic drugs
Andrew Hill
Senior Visiting Research Fellow
Liverpool University, Liverpool, UK
14.15hFinancial models for high- and low income countries
Pieter Walhof
Director PharmAccess and Health Insurance Fund
PharmAccess Foundation, Amsterdam, the Netherlands

14.35hBuilding global capacity
Stefano Vella
Chair of Global Health
Istituto Superiore di Sanità
14.55hRound table Discussion
15.30hProgram adjournment



A comprehensive program has been set up  with the following topics: 
• Unmet needs and challenges of the current alternative of treatment
• Optimization of the management of HIV
• Management of resistance in resource-limited settings
• Management of co-morbidities and co-infection
• Pediatric and Adolescent HIV Care
• The future in HIV care

The presentations of the courses can be found here

For speakers, please go to the "Faculty" page.

The country specific programs can be downloaded here.

Final Agenda_South Africa

FINAL Agenda_Botswana

FINAL Agenda_Kenya

Final Agenda_Namibia

After following this course, the participant will:
• Have an updated knowledge on the current treatment strategies
• Have insight in the management of co-morbidities
• Be able to recognize resistance characteristics of antiretroviral drugs
• Be able to identify potential drug-drug interactions



ACHA 2018 program consists of HIV, Hepatology, HBV, HCV, Co-infections and Public Health session. Please click on here to download the PDF version of the program or the image below to view the agenda online. The information is subject to change.





  • Please download your copy of the APACC 2016 program here.
  • Satellite symposia information can be found here.

Confirmed speakers




We are proud to present the final program of the 6th International Workshop on HIV & Aging: 6th HIV & Aging_PROGRAM

Invited speakers


We are proud to announce that the program has been set. For a full overview of the program, please click here.

The following speakers have confirmed their participation:



The Organizing Committee proudly presents the workshop program: Program HBVCure Workshop 2016.

 Wednesday 9 November 2016

  Session 1
  Chairs: Fabien Zoulim and Scott Fung

08.45 AMLampertico, Pietro 2013Current Status of HBV Therapy
Pietro Lampertico, MD, PhD
University of Milan, Italy University of Milan, Italy
09.05 AMJanssen, Harry 2013Why do we need new treatments and what is our definition of cure?
Harry Janssen, MD, PhD
Toronto Centre for Liver Disease, Canada
09.25 AMDiscussion
09.45 AMCoffee break & Group Picture
  Session 2
  Chairs: Stephen Locarnini and Charles Boucher
10.30 AMNew Treatment Options: Virological Approach
 - Entry inhibition
Urban, Stephen, 2016 120x160Stephan Urban, PhD
Heidelberg University, Germany
 - CCC – DNA inhibition
Levrero, Massimo 2016 120Massimo Levrero, MD
University La Sapienza, Rome, Italy
 - Small interfering RNA’s
Locarnini, Stephen 2015_120x160Stephen Locarnini, BSc, PhD, MBBS, FRC
Victorian Infectious Diseases Reference Laboratory Melbourne, Australia
 - New Nucleoside Analogue & Capsid inhibition
Zoulim, Fabien 2011_120Fabien Zoulim, MD, PhD
INSERM, Villejuif, France
 - Assembly and Secretion Inhibitors
©Allure West Studios.Tim Block, PhD
Hepatitis B Foundation, Doylestown, USA
  Session 3
  Chairs: Mala Maini and Jordan Feld
01.30 PMHow does HBV interact with the immune system?
Thimme, Robert 2016Robert Thimme, MD
University of Freiburg, Germany
01.55 PMNew Treatment options: Immunomodulatory Agents
 - Therapeutic Vaccines 
Chang, Khyong-Mi 120x160Kyong-Mi Chang, MD
University of Pennsylvania, Philadelphia, USA
 - Adaptive Immunity: - PDL Blockers
Maini, Mala 2016Mala Maini, Prof.
University College London, UK
 - Innate Immunity
Gehring, Adam 2014Adam Gehring, PhD
Toronto Centre for Liver Disease, Canada
02.40 PMDiscussion
0300 PMCoffee break
  Session 4
  Chairs: Harry Janssen and Stephan Urban
03.30 PMHow to combine new treatments? Scientific approach
Jordan Feld, MD
Toronto Centre for Liver Disease, Canada
03.50 PMHow to combine new treatments? Clinical approach
Marion Peters, MD
University of California, San Francisco, USA
04.10 PMDiscussion
04.30 PMRoundtable discussion "trial design, treatment endpoints and regulatory approach”.
05.30 PMClosure and adjournment, followed by a workshop dinner




3rd CEE CEE Meeting on Viral Hepatitis and Co-infection with HIV_Program

Wednesday 27 September - Day 1

8:30 Registration and breakfast
9:00 Opening of the Meeting
Session 1: Epidemiology / access to treatment

Local situation in in Slovenia and Balkan Countries
Mojca Maticic, MD, PhDUniversity Medical Centre Ljubljana, Slovenia


Local situation in Ukraine
Olga Golubovska, MD - Bogomolets National medical University, Ukraine

9:30 Local situation in Russia
Vadim Rassokhin, MD  - First St. Petersburg State Medical University named Acad IP Pavlov, Russia
9:40 Local situation in Romania
Oana Sandulescu, MD, PhD - Carol Davila University of Medicine and Pharmacy, Romania
9:50 Local situation in Baltic Countries
Saulius Caplinskas, MD, PhD - Lithuanian Centre for Communicable Diseases and AIDS, Lithuania
10:00 Local situation in Georgia
Akaki Abutidze, MD, MPH - AIDS and Clinical Immunology Research Centre, Georgia
10:10Local situation in Czech and Slovak Republics
Viktor Aster, MD, PhD - Charles University, Czech Republic
10:20 Local situation in Turkey
Cihan Yurdaydin, MD, PhD - University of Ankara, Turkey
10:30Local situation in Poland
Andrzej Horban, MD, PhD - University of Warsaw, Poland
10:40 Local situation in Hungary
Béla Hunyady, MD - Somogy County Kaposi Mór Teaching Hospital, Hungary
10:50 Coffee Break
11:15 Hep-CORE study: management of HBV and HCV infections throughout Europe
Jeffrey Lazarus, PhD - Copenhagen University Hospital, Denmark
11:40 New testing strategies for HCV: how can we achieve the WHO targets?
Mario Poljak, MD, PhD - University of Ljubljana, Slovenia

Round table discussion: access to HepC treatment

Introduction to Access to hepC treatment in EECA
Liudmyla Maistat - Medicines Patent Pool, Switzerland

Key barriers to hepC treatment for PWIDs
Eberhard Schatz - Corellation Network, the Netherlands

Direct price negotiations
Natalia Kravchenko - Alliance for Public Health, Ukraine

Compulsory licensing and patent opposition
Sergey Golovin - Treatment Preparedness Coalition, Russia

MPP progress in VL
Liudmyla Maistat - Medicines Patent Pool, Switzerland

13:00Group picture
13:15Lunch break
14:00Industry-sponsored symposium
Session 2: Challenges in the management of HCV infected patients
15:00 Management of HCC in HCV -infected patients
Markus Peck-Radosavljevic, MD - Klinikum Klagenfurt am Wörthersee, Austria
15:30Clinical case: re-treatment of HCV DAA failure with 3-class resistance
Pavel Khaykin, MD - MainFachArzt, Germany
15:50 Discussion
16:00 Coffee break
Session 3: Epidemiology, clinical presentation and management of Hepatitis E virus
16:30Management of Hepatitis E virus
Heiner Wedemeyer, MD - Medical School Hannover, Germany
17:15Industry-sponsored symposium
18:15Welcome reception and poster viewing
19:00Networking dinner - pre-registration required

Thursday 28 September - Day 2

8:30 Industry-sponsored symposium
Session 4: Treatment challenges in HIV & HCV – special populations

Special challenges in curbing the HIV epidemic in Central/Eastern Europe
Miłosz Parczewski, MD, PhD - Pomeranian Medical University, Szczecin, Poland

Abstract - driven presentations:

10:00 Results of Hepatitis C virus (hcv) treatment program among people with hiv/hcv co-infection who inject drugs (PWID)
Mr. Sergii Filipovich
10:10 HIV infection outbreak among IDUs in Minsk
Prof. Vladimir Eremin


10:30Coffee break
Session 5: Abstract - driven presentations
11:00Real-world effectiveness of ledipasvir/sofosbuvir in hepatitis C virus genotype 1, 2 and 3 infection: single-center experience within Georgian hepatitis C elimination program
Prof. Tengiz Tsertsvadze
11:10 Clinical characteristics of patients seeking care for chronic HCV infection – results from the large observational study in Central and Eastern European region and Kazakhstan (MOSAIC Study)
Dr. Béla Hunyady
11:20Changes in demographic, epidemiological and virological characteristics of patients with chronic hepatitis B virus infection in Slovenia between 1997 and 2010
Dr. Nina Kmet Lunarcek
11:30 Prognostic factors for liver fibrosis regression following sustained virologic response in patients with hepatitis C treated with direct acting antivirals
Dr. Oana Sandulescu
11:40 Direct-acting antivirals Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir with or without Ribavirin in HCV genotype 1-infected treatment-naïve or treatment-experienced patients with or without cirrhosis: real-life experience in Lithuania and Latvia
Dr. Ligita Jancoriene
11:50 Discussion
Special session: Future directions of ARVs
12:00Virologist Perspective
Charles Boucher, MD, PhD - Erasmus University, the Netherlands
12:15Clinician Perspective
Jonathan Schapiro, MD - Sheba Medical Centre, Israel
12:30Pharmacologist Perspective
Saye Khoo, MD, PhD - University of Liverpool, United Kingdom


13:00Lunch break
Session 6 Future in Diagnostic & Therapeutic Approaches

Innovative diagnostics for HIV, HBV and HCV
Dan Otelea, MD, PhD - Nat. Institute for Inf. Diseases “Prof. Dr. Matei Bals”, Romania

14:15The challenges in hepatitis B vaccination
Pierre Van Damme, MD, PhD - University of Antwerpen, Belgium
15:00Closing remarks





We are privileged to have an excellent team of invited speakers join us at this year's meeting on the latest developments in antiviral therapy for HIV, HCV and HBV.

Downloadable versionProgram 15th European Meeting on HIV & Hepatitis



Draft program

10.00 AMRegistration & Coffee
10.30 AMOpening of the workshop
Topic 1:
Current Management of the Patient with Hepatitis C
10.45 AMIs Resistance testing in 2017 still relevant
11.15 AMDiscussion
Topic 2:
Use of HCV positive donors
11.30 AMThe US perspective (15 min.)
 The European perspective (15 min.)
 The Asian perspective (15 min.)
 Panel Discussion ( 30 - 45 min.)
1.00 PMLunch
Topic 3:
Management guidance for Chronic Hep B and Hep E
2.00 PMPost transplant management: Do we need guidelines for HBV
2.30 PMDiscussion
2.45 PMClinical case discussions
 Hepatitis E patient
3.30 PMCoffee Break
Topic 4:
BMI 50 - Next Frontier in Transplantation
4.00 PMUK policy: stop smoking and lose weight
4.20 PMBariatric procedures for NASH in the setting of Transplantation - Endoscopic procedures
4.40 PMBariatric procedures for NASH in the setting of Transplantation - Surgery
5.00 PMDiscussion
5.30 PMClosure


The 12th International workshop on HIV Transmission meeting aims to enhance the integration of all relevant disciplines to constrain the spread of (drug-resistant) HIV and to provide a forum to discuss the various aspects of the transmission of HIV. The meeting's distinctive format will create a lively dialogue amongst panelists, engage attendees in discussions, and identify the best ways to move research forward.

Below the preliminary program for the International workshop on HIV Transmission is published. Please note that this program is subject to change.

Download program as PDF (version 13 July 2017):

Program Transmission



Friday 21 July

10.00 - 11.00 hRegistration
11.00 h

Christiane Moog & Eric Hunter

  Session 1: Prevention strategies
  Chairs: Christiane Moog & Eric Hunter

11.30 h Invited lecture: Vaccine induced susceptibility vs protection
Roger LeGrand
Comissariat à l'Energie Atomique, Fontenay-aux Roses, France
  Abstract-driven presentations
12.00 - 12.15 hIdentification of rapid and emerging transmission clusters from genetic network
Tsz Ho Kwa
Jockey Club School Of Public Health And Primary Care, The Chinese University Of Hong Kong, Hong Kong
12.15 - 12.30 hPhylogenetic, epidemiological and virological insights on the rise of large cluster outbreaks fueling the HIV-1 epidemic among Men having sex with Men within Quebec
Bluma Brenner
Lady Davis Institute, Canada
12.30 - 12.45 hA novel NRTI, EFdA, effectively penetrates and suppresses HIV infection in all individual compartments of male genital tract
Martina Kovarova
University Of North Carolina At Chapel Hill, USA
12.45 h Discussion & evaluation forms
13.15 hLunch break
  Session 2: Blocking HIV Transmission
  Chairs: Gabriella Scarlatti & Stacy Carrington Lawrence

14.15 h Invited lecture: Passive antibody to block transmission
Mike Cohen, MD
UNC Centers for AIDS Research, The University of North Carolina at Chapel Hill, Chapel Hill, USA
  Abstract-driven presentations
14.45 h A Combination of Broadly Neutralizing Antibodies Prevents In Vitro SHIV162P3 Cell-Free Transmission More Efficiently Than Cell-to-Cell Transmission
Karunasinee Suphaphiphat
CEA, France
15.00 h Broadly neutralizing antibody against HIV-1 Env blocks infection of the first cell after mucosal challenge of macaques
Christiane Stahl-Hennig
Deutsches Primatenzentrum GmbH, Germany
15.15 h Non-neutralizing Antibodies Targeting HIV’s V1V2 Domain Exhibit Strong Inhibitory Activities
Luzia Mayr
Inserm U1109, France
15.30 h Discussion & evaluation form
16.00 hCoffee Break
  Session 3: Round table discussion: Making PrEP a succes
  Chairs: Tom Hope & Gina Brown

16.30 h Invited lecture: Behaviour perspective
Ian McGowan, MD, PhD, FRCP
University of Pittsburgh, Pittsburgh, USA
17.00 h Invited lecture: Clinical perspective 
Annemarie Wensing, MD, PhD
University Medical Center Utrecht, the Netherlands
  Abstract-driven presentation
17.30 h New formulation of injectable and removable long-acting dolutegravir is effective in prevention of HIV transmission with high dose vaginal HIV challenges
Martina Kovarova
University Of North Carolina At Chapel Hill, USA
17.45 h Round table discussion
  Guided Poster Tour
  Chairs: Gina Brown & Eric Hunter

18.15 h Evaluating the feasibility of implementing UNAIDS' 90 90 90 strategy, achieving universal access to treatment, and eliminating HIV in Malawi
Laurence Palk
University Of California, Los Angeles, USA 
18.15 h OLA-Simple 1.0: Laboratory Kit for HIV Drug Resistance Testing in Low-Resource Settings
Nuttada Panpradist 
University Of Washington, USA
18.15 hCouples HIV Testing and Counseling for Heterosexual Pregnant Women and their Partners Seeking Prenatal Care in Philadelphia, PA
Itoro Inoyo
Drexel University College of Medicine, Division of Infectious Diseases & HIV Medicine, USA
18.15 h An HIV Risk Assessment Tool to Predict HIV Transmission within HIV Serodiscordant Couples
Kristin Wall
Emory University, USA
19.30 hNetwork dinner

Saturday 22 July

   Session 4: Early events of HIV Transmission
   Chairs: Walid Heneine & Jean Patterson

08.30 h Invited lecture: Trafficking of HIV out of the mucosa
Claudia Cicala, PhD
NIAID, Bethesda, USA
  Abstract-driven presentations
09.00 h Defining the first phases of penetration and infection of HIV/SIV into the mucosal tissues
Camille Ducloy
Inserm UMR 1109, France
09.15 hIntestinal Dendritic Cells and Macrophages Play a Different Role in the Early Events of HIV-1 Transmission.
Mariangela Cavarelli
Cea, France
09.30 hThe impact of specific N-linked glycosylation patterns on HIV-1 transmission fitness
Katja Klein
University Of Western Ontario, Canada
09.45 hDiscussion & evaluation form
10.00 hCoffee break & Poster Viewing
  Session 5:  Post Transmission Events
  Chairs: Eric Arts & Phylis Kanki

  Abstract-driven presentations
10.30 hGut Dysbiosis During Acute HIV Infection
Angela Wahl
University Of North Carolina At Chapel Hill,USA
10.45 hHIV-1 Vif adaptation to host immune pressure impact of cytidine deaminases and host HLA.
Nicole Reddy
Africa Health Research Institute , South Africa
11.00 hDeep sequencing reveals viral evolution in Gag within protective HLA alleles B*57:02, B*58:01 and B*7 supertype individuals acutely infected with HIV-1 subtype C in Durban, South Africa
Kamini Gounder 
Hiv Pathogenesis Programme, University Of Kwa-zulu Natal, South Africa
11.15 hUnexpected antibody isotypes and neutralizing profile in patients controlling HIV
Jéromine Klingler
Inserm Umr_s 1109, Francexx
11.30 hTransmitted drug-resistance in newly diagnosed HIV drug-naïve individuals in Portugal
Marta Sofia Pingarilho
Ihmt, Portugal
11.45 hDiscussion & evaluation form
12.00 hLunch
  Session 6: Round table discussion: Using transmission networks for targeted interventions
  Chairs: Anne Wensing & Jan Albert

13.00 h Introduction: Using transmission networks for targeted interventions
Charles Boucher, MD, PhD
Erasmus Medical Centre, Rotterdam, The Netherlands
13.15 h Round table discussion
14.00 hClosure of the Workshop



  • Please find below the latest version of the program agenda, including accepted oral and poster presentations. You can also download a copy of the program HERE.
  • Missed the 2nd edition? You can view the presentations and the videos on the Infectious Diseases Online.


Last updated: 2017-10-06

Thursday, October 19, 2017

Key note
Chair: Alan Landay 
09:30hBrain-Gut-Microbiota interactions and intestinal health
Wendy Henderson, NINR, NIH, DHHS
Session 1: Pathogenesis
Chairs: Cara Wilson & Stacy Carrington-Lawrence
10:30hMining adaptive immunity to identify disease-promoting microbiota members in HIV
Ivan Vujkovic-Cvijin, National Institutes of Health, Mucosal Immunology Section, USA
11:00hMicrobial colonization of the gut and brain development in infancy
Rebecca Knickmeyer, UNC School of Medicine, UNC-Chapel Hill, USA
11:30hDifferential responses of colonic ILCs to gut commensal bacteria altered during HIV infection (Abstract #: O_01)
Moriah Castleman, USA
11:45hMicrobial dysbiosis does not alter immune activation or disease progression in SIV-infected rhesus macaques (Abstract #: O_02)
Alexandra Ortiz, USA
12:00hDiscussion & Session Evaluation
12:15hGroup Photo & Lunch Break
Session 2: Transmission & Prevention
Chairs: Laurel Lagenaur & Piotr Nowak
13:15hMicrobe: drug interactions and the impact on HIV infection and pathogenesis 
Nichole Klatt, University of Washington, USA
13:45hCervicovaginal microbial dynamics and its impact on HIV acquisition risk
Douglas Kwon, Ragon Institute of MGH, MIT and Harvard, USA
14:15Vaginal lactic acid inhibits production of pro-inflammatory mediators from human cervicovaginal epithelial cells associated with HIV acquisition (Abstract #: O_03)
Gilda Tachedjian, Australia
14:30Discussion & Session Evaluation
14:45Break & Poster Viewing (Abstract #: O_01 - O_04, P_01 - P_08) 
Session 3: GI Tract and Diet
Chairs: Nichole Klatt & Satya Dandekar

Detrimental impact of a high fat diet on the natural history of SIV infection in non-human
Ivona Pandrea, University of Pittsburgh, USA


Milk - guiding the infant microbiome 
Bruce German, University of California, Davis, USA

16:30hUnderstanding complexities of gut microbiome dysbiosis in HIV infected populations using a large cohort (Abstract #: O_04)
Abigail Armstrong, USA
16:45hPlasma tryptophan-kynurenine metabolites are altered with gut microbiota dysbiosis in HIV infection and associated with progression of carotid artery atherosclerosis (Abstract #: O_09)
Qibin Qi, USA
17:00hDiscussion & Session Evaluation

Friday, October 20, 2017

Session 4: Comorbidities
Chairs: Alan Landay & Ronald Collman 
09:00hInflammatory bowel disease (IBD) and colon cancer and microbiome
William DePaolo, University of Washington, USA
09:30hMicrobial metabolites in HIV pathogenesis and comorbidities
Dana Gabuzda, Harvard Medical School, USA
10:00hComposite analysis of bacteriome and virome from HIV/HPV-coinfected pregnant women reveals proxies for intraepithelial lesions and immunodeficiency status (Abstract #: O_05)
Marcelo Soares, Brazil
10:15hDiscussion & Session Evaluation
10:30hBreak & Poster Viewing (Abstract #: O_05 - O_09, P_10 - P_16)
Session 5: Microbiome & Vaccines
Chairs: Que Dang & Angela Malaspina

Aging, the microbiome and vaccine responses
Daria Hazuda, Merck, USA


Mechanisms intersecting microbiota metabolomics with gut epithelial barrier repair in HIV infection
Satya Dandekar, University of California, Davis, USA

12:30hRole of the microbiome in HIV vaccine response heterogeneity
James Kublin, Fred Hutch and University of Washington, USA
13:00hEffect of high-risk sexual behaviour on diversity of the vaginal microbiota and abundance of lactobacillus (Abstract #: O_06)
Jocelyn Wessels, Canada
13:15h Discussion & Session Evaluation
13:30hLunch break
Session 6: Metabolomics Biologic and Technical issues
Chairs: Frederic Bushman & Roger Paredes
14:30hStudying the functional microbiome in vivo in HIV by metaproteomics approaches
Adam Burgener, University of Manitoba, Canada

Fatty acid profiles differ in HIV infection, persist despite suppressive ART, and are associated with immune activation
Nicholas Funderburg, Ohio State University College of Medicine, USA

15:30hModulation of gut microbiota by indoleamine 2,3-dioxygenase 1 inhibitor during antiretroviral suppressed SIV infection in rhesus macaques (Abstract #: O_07)
Zhang Wang, USA
15:45hThe microbial-derived short chain fatty acid butyrate directly and differentially inhibits gut T helper cell subset activation and proliferation (Abstract #: O_08)
Jon Kibbie, USA
16:00hDiscussion & Session Evaluation
16:30hClosing remarks by workshop chair


Paper ref. # TitlePresentation author
P_01Management of neurocognitive impairment in HIV patientsJason Brenchley, Italy
P_02Effects of advanced HIV disease on the dormant blood microbiotaSergio Serrano-Villar, Spain
P_03A role for dysbiotic bacteria in increased gastrointestinal neutrophil lifespan in treated HIV infectionTiffany Hensley-Mcbain, USA
P_04FuMi: A novel functional microbiome tool for metaproteomic datasets identified key bacterial pathways altered with pregnancy Sarah Mutch, Canada
P_05Depot-Medroxyprogesterone Acetate (DMPA) is associated with diversity of the vaginal microbiota and an altered vaginal microenvironment Jocelyn Wessels, Canada
P_06Cloud-based microbiome, metagenomic, and pathogen analysisHsinyi Tsang, USA
P_07Isolation of translocating bacteria in progressive SIV infection of rhesus macaques Jacob Flynn, USA
P_08Innovative pilot program on the diagnosis and management modulation of the diseases caused in the oral microbiomeKishore Shetty, USA
P_10Epidemiology of HIV/AIDS and syphilis among high risk groups in Pakistan Usman Waheed, Pakistan
P_11Promoting and creating awareness of HIV/AIDS in the black african communities in luton, United KingdomNelson Anti, UK
P_12Mobile HIV counselling and testing outreach: a model for community based approach to increasing uptake of HCT and antiretroviral therapy services in Benue State NigeriaGreg Abiaziem, Nigeria
P_13HIV-associated microbiome differences, geography, and inflammationDavid B Gootenberg, USA
P_14Microbiome Profiles of Chronic HIV-1 Infection under HAARTJemal Ali Mahdi, Ethiopia
P_15Molecular Epidemiology of HIV/AIDS in PakistanUsman Waheed, Pakistan
P_16Fecal microbiota composition drives immune activation in HIV-infected individualsCatherine Lozupone, USA



The program of the Latin American Meeting on Viral Hepatitis and HIV Co-infection is currently being developed. A preliminary program can be downloaded here: PROGRAM

Invited speakers



An exciting new program is being set up.
A Newsletter will be sent out as soon as registration opens and the new program is available.

The program of January 2014 is available by clicking on Final Program 4th HIV & Women



We are proud to announce that the program has been set. For a full overview of the program, please click on the online program (righthand side of the website) or refer to the Program.

Please click here for more information on the Satellite Symposia.


The Organizing Committee has developed a great program:
Click on the right for ONLINE PROGRAM and time schedule.
A program in pdf format can be downloaded here: Program 9th HIV Transmission ws 2014

All invited speakers:







Click on the Online Program button (or your right hand side) to view the final version of the program.

The following invited speakers have confirmation their contribution:


The Organizing Committee is currently finalizing the program. More information will be posted in due course. For a program outline, please visit the website of the 14th European Meeting on HIV & Hepatitis.



 The Organizing Committee proudly presents the final workshop program: Final program 17HIVHEPPK

The following invited speakers have confirmed their contribution: